| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepacivirus | 191 | 2024 | 1342 | 19.780 |
Why?
|
| Hepatitis C | 161 | 2024 | 1594 | 19.560 |
Why?
|
| Hepatitis C, Chronic | 127 | 2023 | 1032 | 17.840 |
Why?
|
| Antiviral Agents | 185 | 2024 | 3070 | 16.000 |
Why?
|
| Liver Cirrhosis | 111 | 2024 | 1959 | 8.850 |
Why?
|
| Hepatitis B, Chronic | 47 | 2024 | 413 | 8.200 |
Why?
|
| Interferon-alpha | 59 | 2024 | 909 | 6.650 |
Why?
|
| Hepatitis B virus | 41 | 2024 | 531 | 6.010 |
Why?
|
| Carcinoma, Hepatocellular | 62 | 2024 | 2330 | 5.580 |
Why?
|
| Liver Neoplasms | 62 | 2024 | 4357 | 4.590 |
Why?
|
| Virus Replication | 40 | 2023 | 2457 | 4.580 |
Why?
|
| Ribavirin | 50 | 2021 | 395 | 4.430 |
Why?
|
| Hepatitis B | 31 | 2024 | 710 | 4.390 |
Why?
|
| Liver Transplantation | 54 | 2024 | 2416 | 3.970 |
Why?
|
| Hepatic Encephalopathy | 11 | 2022 | 143 | 3.730 |
Why?
|
| Interferons | 39 | 2021 | 716 | 3.490 |
Why?
|
| Liver | 68 | 2024 | 7578 | 3.260 |
Why?
|
| Liver Diseases | 21 | 2024 | 1304 | 3.090 |
Why?
|
| HIV Infections | 90 | 2024 | 17542 | 3.030 |
Why?
|
| Liver Failure, Acute | 16 | 2018 | 182 | 2.650 |
Why?
|
| Polyethylene Glycols | 34 | 2024 | 1188 | 2.650 |
Why?
|
| Interleukins | 13 | 2018 | 796 | 2.450 |
Why?
|
| Hepatocytes | 21 | 2024 | 1247 | 2.270 |
Why?
|
| RNA, Viral | 52 | 2021 | 2867 | 2.180 |
Why?
|
| Hepatitis B Surface Antigens | 20 | 2024 | 294 | 2.160 |
Why?
|
| Fatty Liver | 16 | 2024 | 811 | 1.880 |
Why?
|
| Viral Nonstructural Proteins | 17 | 2019 | 228 | 1.690 |
Why?
|
| Protease Inhibitors | 10 | 2015 | 750 | 1.610 |
Why?
|
| Host-Pathogen Interactions | 14 | 2022 | 1466 | 1.610 |
Why?
|
| Hepatic Stellate Cells | 11 | 2024 | 117 | 1.600 |
Why?
|
| End Stage Liver Disease | 14 | 2024 | 369 | 1.600 |
Why?
|
| Humans | 563 | 2024 | 767040 | 1.520 |
Why?
|
| Hepatitis B e Antigens | 16 | 2024 | 135 | 1.320 |
Why?
|
| Viral Load | 38 | 2024 | 3385 | 1.270 |
Why?
|
| Hepatitis B Core Antigens | 8 | 2023 | 90 | 1.260 |
Why?
|
| Transforming Growth Factor beta1 | 7 | 2024 | 637 | 1.240 |
Why?
|
| Acute Kidney Injury | 12 | 2024 | 1946 | 1.230 |
Why?
|
| Alanine Transaminase | 19 | 2022 | 609 | 1.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 13 | 2022 | 3249 | 1.110 |
Why?
|
| HIV | 18 | 2023 | 1591 | 1.090 |
Why?
|
| Virus Activation | 6 | 2020 | 322 | 1.080 |
Why?
|
| Tissue Donors | 13 | 2023 | 2387 | 1.070 |
Why?
|
| Middle Aged | 241 | 2024 | 223233 | 1.060 |
Why?
|
| Aspartate Aminotransferases | 11 | 2021 | 415 | 1.050 |
Why?
|
| Male | 301 | 2024 | 364203 | 1.050 |
Why?
|
| Cryoglobulinemia | 7 | 2018 | 84 | 1.050 |
Why?
|
| Uridine Monophosphate | 6 | 2019 | 67 | 1.020 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 3 | 2012 | 178 | 1.010 |
Why?
|
| DNA, Viral | 21 | 2023 | 2201 | 1.010 |
Why?
|
| Genotype | 46 | 2022 | 13035 | 0.950 |
Why?
|
| Drug Therapy, Combination | 39 | 2021 | 6310 | 0.940 |
Why?
|
| NF-kappa B | 7 | 2016 | 2493 | 0.940 |
Why?
|
| Female | 276 | 2024 | 396660 | 0.910 |
Why?
|
| Recombinant Proteins | 38 | 2024 | 6507 | 0.890 |
Why?
|
| Hepatitis, Alcoholic | 4 | 2024 | 110 | 0.880 |
Why?
|
| STAT1 Transcription Factor | 6 | 2014 | 341 | 0.850 |
Why?
|
| Viremia | 15 | 2023 | 726 | 0.850 |
Why?
|
| Adult | 209 | 2024 | 223317 | 0.850 |
Why?
|
| Elasticity Imaging Techniques | 7 | 2023 | 399 | 0.840 |
Why?
|
| Cholangitis, Sclerosing | 3 | 2022 | 179 | 0.830 |
Why?
|
| Guanine | 5 | 2024 | 280 | 0.830 |
Why?
|
| DNA, Circular | 2 | 2022 | 97 | 0.820 |
Why?
|
| Gene Expression Regulation | 18 | 2021 | 11923 | 0.810 |
Why?
|
| Lipase | 2 | 2016 | 320 | 0.770 |
Why?
|
| Drug Resistance, Viral | 10 | 2019 | 868 | 0.760 |
Why?
|
| Hepatitis C Antibodies | 9 | 2013 | 151 | 0.760 |
Why?
|
| Organ Transplantation | 4 | 2020 | 1173 | 0.750 |
Why?
|
| Nobel Prize | 1 | 2021 | 46 | 0.750 |
Why?
|
| Kidney Transplantation | 17 | 2021 | 4268 | 0.730 |
Why?
|
| Waiting Lists | 8 | 2024 | 778 | 0.710 |
Why?
|
| Disease Progression | 38 | 2023 | 13646 | 0.700 |
Why?
|
| Proline | 9 | 2022 | 454 | 0.700 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 100 | 0.700 |
Why?
|
| Speech Disorders | 1 | 2021 | 178 | 0.700 |
Why?
|
| Growth Hormone-Releasing Hormone | 5 | 2021 | 126 | 0.690 |
Why?
|
| Cholestasis | 2 | 2022 | 385 | 0.690 |
Why?
|
| Gastroenterology | 6 | 2020 | 593 | 0.690 |
Why?
|
| Iron | 4 | 2024 | 1811 | 0.680 |
Why?
|
| Virus Internalization | 5 | 2017 | 504 | 0.680 |
Why?
|
| Fluorenes | 4 | 2019 | 160 | 0.670 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2021 | 694 | 0.670 |
Why?
|
| Benzimidazoles | 6 | 2020 | 862 | 0.650 |
Why?
|
| Insulin Resistance | 11 | 2022 | 3986 | 0.650 |
Why?
|
| Aged | 109 | 2024 | 171319 | 0.650 |
Why?
|
| Defecation | 1 | 2020 | 191 | 0.640 |
Why?
|
| Hepatorenal Syndrome | 6 | 2024 | 76 | 0.630 |
Why?
|
| MicroRNAs | 7 | 2020 | 3792 | 0.610 |
Why?
|
| Immunity, Innate | 6 | 2019 | 3076 | 0.610 |
Why?
|
| Lamivudine | 6 | 2021 | 367 | 0.610 |
Why?
|
| Cell Line | 21 | 2020 | 15567 | 0.610 |
Why?
|
| Fibrosis | 14 | 2023 | 2078 | 0.600 |
Why?
|
| Phosphatidylinositol Phosphates | 3 | 2015 | 201 | 0.600 |
Why?
|
| Albuminuria | 2 | 2019 | 658 | 0.600 |
Why?
|
| Liver Function Tests | 10 | 2021 | 526 | 0.600 |
Why?
|
| Polymorphism, Single Nucleotide | 19 | 2024 | 16036 | 0.590 |
Why?
|
| Renal Artery | 3 | 2017 | 355 | 0.590 |
Why?
|
| Paracentesis | 2 | 2016 | 99 | 0.590 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2014 | 195 | 0.580 |
Why?
|
| Angiopoietin-2 | 1 | 2019 | 186 | 0.580 |
Why?
|
| Transplants | 1 | 2020 | 208 | 0.570 |
Why?
|
| Severity of Illness Index | 28 | 2024 | 15925 | 0.570 |
Why?
|
| CD8-Positive T-Lymphocytes | 17 | 2023 | 4648 | 0.570 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 2 | 2014 | 71 | 0.570 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 5 | 2016 | 2887 | 0.560 |
Why?
|
| Feces | 3 | 2021 | 1508 | 0.560 |
Why?
|
| Apolipoprotein B-100 | 2 | 2016 | 157 | 0.540 |
Why?
|
| Signal Transduction | 26 | 2024 | 23621 | 0.540 |
Why?
|
| Treatment Outcome | 68 | 2024 | 65295 | 0.540 |
Why?
|
| Oligopeptides | 6 | 2015 | 1195 | 0.540 |
Why?
|
| Retroperitoneal Space | 1 | 2017 | 175 | 0.540 |
Why?
|
| Alcohol Deterrents | 1 | 2016 | 49 | 0.540 |
Why?
|
| Disulfiram | 1 | 2016 | 63 | 0.540 |
Why?
|
| Adenomyoma | 1 | 2016 | 8 | 0.540 |
Why?
|
| eIF-2 Kinase | 4 | 2016 | 146 | 0.540 |
Why?
|
| Speech | 1 | 2021 | 555 | 0.530 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2016 | 440 | 0.530 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 2 | 2016 | 100 | 0.530 |
Why?
|
| Cytokines | 13 | 2024 | 7446 | 0.520 |
Why?
|
| Cyclopropanes | 5 | 2021 | 436 | 0.520 |
Why?
|
| Keratin-18 | 2 | 2012 | 37 | 0.520 |
Why?
|
| HIV-1 | 19 | 2017 | 6951 | 0.520 |
Why?
|
| Papilloma, Inverted | 1 | 2015 | 19 | 0.510 |
Why?
|
| Lactams, Macrocyclic | 5 | 2021 | 319 | 0.510 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2016 | 95 | 0.510 |
Why?
|
| Ribonucleoprotein, U5 Small Nuclear | 1 | 2015 | 7 | 0.500 |
Why?
|
| Reactive Oxygen Species | 4 | 2022 | 2144 | 0.500 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2019 | 2299 | 0.500 |
Why?
|
| Biopsy | 19 | 2021 | 6777 | 0.490 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2023 | 162 | 0.490 |
Why?
|
| Peptide Elongation Factors | 1 | 2015 | 59 | 0.490 |
Why?
|
| Fatty Acids | 2 | 2021 | 1806 | 0.490 |
Why?
|
| Unfolded Protein Response | 3 | 2016 | 239 | 0.490 |
Why?
|
| Carbamates | 5 | 2020 | 191 | 0.490 |
Why?
|
| Epidermal Growth Factor | 2 | 2016 | 697 | 0.480 |
Why?
|
| RNA, Small Interfering | 10 | 2016 | 3427 | 0.480 |
Why?
|
| Macrocyclic Compounds | 4 | 2020 | 67 | 0.480 |
Why?
|
| Cell Line, Tumor | 21 | 2022 | 17097 | 0.470 |
Why?
|
| Aneurysm, False | 1 | 2017 | 263 | 0.470 |
Why?
|
| Viral Core Proteins | 6 | 2011 | 158 | 0.460 |
Why?
|
| Gallbladder Neoplasms | 1 | 2016 | 190 | 0.460 |
Why?
|
| Spliceosomes | 1 | 2014 | 116 | 0.460 |
Why?
|
| Markov Chains | 3 | 2017 | 976 | 0.460 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2022 | 1515 | 0.450 |
Why?
|
| Endoribonucleases | 1 | 2016 | 231 | 0.450 |
Why?
|
| Glomerular Filtration Rate | 5 | 2020 | 2227 | 0.450 |
Why?
|
| Tissue and Organ Procurement | 2 | 2019 | 987 | 0.450 |
Why?
|
| Nutrition Disorders | 1 | 2014 | 204 | 0.440 |
Why?
|
| Gallstones | 1 | 2016 | 285 | 0.430 |
Why?
|
| Nose Neoplasms | 1 | 2015 | 250 | 0.430 |
Why?
|
| Diabetes Mellitus | 12 | 2023 | 5886 | 0.420 |
Why?
|
| Kidney | 9 | 2023 | 7063 | 0.420 |
Why?
|
| Sulfonamides | 7 | 2021 | 1982 | 0.420 |
Why?
|
| Cohort Studies | 35 | 2023 | 41718 | 0.420 |
Why?
|
| Hepatitis | 4 | 2023 | 226 | 0.420 |
Why?
|
| Drug Design | 4 | 2015 | 1045 | 0.420 |
Why?
|
| Down-Regulation | 5 | 2021 | 2931 | 0.420 |
Why?
|
| Risk Factors | 52 | 2024 | 74886 | 0.420 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2012 | 28 | 0.410 |
Why?
|
| Kidney Failure, Chronic | 5 | 2019 | 2495 | 0.410 |
Why?
|
| Membrane Proteins | 8 | 2016 | 7868 | 0.400 |
Why?
|
| Animals | 63 | 2024 | 168965 | 0.400 |
Why?
|
| Time Factors | 33 | 2024 | 40154 | 0.400 |
Why?
|
| Albumins | 1 | 2015 | 577 | 0.400 |
Why?
|
| Lipid Metabolism | 6 | 2019 | 1895 | 0.400 |
Why?
|
| ADP-Ribosylation Factor 1 | 1 | 2012 | 43 | 0.390 |
Why?
|
| Immunologic Memory | 6 | 2024 | 1377 | 0.390 |
Why?
|
| Aspirin | 5 | 2024 | 3135 | 0.390 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2015 | 385 | 0.390 |
Why?
|
| Transforming Growth Factor beta | 5 | 2016 | 1995 | 0.390 |
Why?
|
| Aneurysm | 1 | 2015 | 343 | 0.390 |
Why?
|
| Prospective Studies | 39 | 2024 | 54886 | 0.390 |
Why?
|
| Hydroxymethylglutaryl-CoA Synthase | 1 | 2011 | 15 | 0.390 |
Why?
|
| Organic Anion Transporters | 1 | 2012 | 101 | 0.390 |
Why?
|
| Interferon Type I | 4 | 2021 | 568 | 0.390 |
Why?
|
| Aminoisobutyric Acids | 3 | 2020 | 39 | 0.390 |
Why?
|
| Leucine | 4 | 2022 | 547 | 0.380 |
Why?
|
| Transcriptional Activation | 2 | 2022 | 1751 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 8 | 2021 | 7435 | 0.380 |
Why?
|
| Retrospective Studies | 51 | 2024 | 81659 | 0.380 |
Why?
|
| Social Stigma | 1 | 2018 | 788 | 0.380 |
Why?
|
| Liver Regeneration | 3 | 2013 | 214 | 0.380 |
Why?
|
| Pyrophosphatases | 1 | 2011 | 142 | 0.370 |
Why?
|
| Leukocytes, Mononuclear | 6 | 2021 | 1854 | 0.370 |
Why?
|
| Consensus | 2 | 2021 | 3207 | 0.370 |
Why?
|
| Lactones | 2 | 2011 | 315 | 0.370 |
Why?
|
| Polymerase Chain Reaction | 8 | 2016 | 6067 | 0.360 |
Why?
|
| Quinoxalines | 4 | 2020 | 297 | 0.360 |
Why?
|
| Disease Susceptibility | 3 | 2023 | 1791 | 0.360 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2015 | 1897 | 0.360 |
Why?
|
| Immunologic Factors | 5 | 2020 | 1592 | 0.360 |
Why?
|
| Knee | 1 | 2012 | 277 | 0.360 |
Why?
|
| Vascular Malformations | 1 | 2016 | 469 | 0.350 |
Why?
|
| Shoulder | 1 | 2012 | 300 | 0.350 |
Why?
|
| Lipoproteins | 6 | 2022 | 871 | 0.350 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2011 | 1902 | 0.340 |
Why?
|
| Drugs, Investigational | 1 | 2012 | 211 | 0.340 |
Why?
|
| RNA Splicing | 1 | 2014 | 903 | 0.340 |
Why?
|
| STAT Transcription Factors | 1 | 2010 | 189 | 0.340 |
Why?
|
| Genetic Variation | 7 | 2021 | 6611 | 0.340 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2010 | 696 | 0.330 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2014 | 189 | 0.330 |
Why?
|
| Postoperative Complications | 8 | 2018 | 15824 | 0.330 |
Why?
|
| Interleukin-6 | 2 | 2018 | 3227 | 0.330 |
Why?
|
| Cholesterol, LDL | 4 | 2022 | 2392 | 0.330 |
Why?
|
| Ammonia | 2 | 2021 | 244 | 0.330 |
Why?
|
| Mass Screening | 4 | 2014 | 5456 | 0.330 |
Why?
|
| Janus Kinases | 1 | 2010 | 253 | 0.330 |
Why?
|
| Apoptosis | 10 | 2020 | 9513 | 0.330 |
Why?
|
| Anti-Retroviral Agents | 4 | 2022 | 1787 | 0.330 |
Why?
|
| Prognosis | 28 | 2024 | 29963 | 0.330 |
Why?
|
| Follow-Up Studies | 32 | 2024 | 39317 | 0.320 |
Why?
|
| Antigens, Neoplasm | 2 | 2014 | 1997 | 0.320 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 823 | 0.320 |
Why?
|
| Blood Banks | 1 | 2010 | 107 | 0.320 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2015 | 36582 | 0.310 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2008 | 41 | 0.310 |
Why?
|
| Models, Theoretical | 4 | 2018 | 3561 | 0.310 |
Why?
|
| Drug Administration Schedule | 11 | 2019 | 4855 | 0.310 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2009 | 113 | 0.310 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3112 | 0.300 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3234 | 0.300 |
Why?
|
| Terminal Care | 4 | 2021 | 1770 | 0.300 |
Why?
|
| Luminescent Measurements | 1 | 2010 | 342 | 0.300 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2012 | 572 | 0.300 |
Why?
|
| Tendons | 1 | 2012 | 556 | 0.300 |
Why?
|
| Predictive Value of Tests | 17 | 2022 | 15424 | 0.300 |
Why?
|
| North America | 9 | 2021 | 1287 | 0.290 |
Why?
|
| Intra-Abdominal Fat | 5 | 2021 | 624 | 0.290 |
Why?
|
| Gene Expression Profiling | 10 | 2024 | 9532 | 0.290 |
Why?
|
| Dyslipidemias | 4 | 2022 | 872 | 0.290 |
Why?
|
| Recurrence | 14 | 2021 | 8504 | 0.290 |
Why?
|
| Heat Stroke | 2 | 2018 | 29 | 0.290 |
Why?
|
| Hemorrhage | 3 | 2019 | 3464 | 0.290 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2020 | 1354 | 0.290 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2008 | 61 | 0.290 |
Why?
|
| Clinical Trials as Topic | 10 | 2020 | 8048 | 0.290 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 7121 | 0.290 |
Why?
|
| Patient Admission | 2 | 2019 | 1364 | 0.280 |
Why?
|
| Pulmonary Artery | 1 | 2016 | 1944 | 0.280 |
Why?
|
| Porphyria Cutanea Tarda | 1 | 2007 | 12 | 0.280 |
Why?
|
| HLA-C Antigens | 3 | 2021 | 146 | 0.280 |
Why?
|
| Drug Costs | 1 | 2015 | 1196 | 0.280 |
Why?
|
| Epoxy Compounds | 1 | 2007 | 137 | 0.280 |
Why?
|
| Renal Replacement Therapy | 3 | 2024 | 281 | 0.280 |
Why?
|
| Lipids | 3 | 2017 | 3322 | 0.280 |
Why?
|
| CD4-Positive T-Lymphocytes | 12 | 2017 | 4405 | 0.270 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2009 | 249 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2021 | 10748 | 0.270 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2014 | 2428 | 0.270 |
Why?
|
| Cost of Illness | 2 | 2016 | 1951 | 0.270 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2006 | 24 | 0.270 |
Why?
|
| DNA Primers | 9 | 2014 | 2827 | 0.270 |
Why?
|
| Macrophage Activation | 3 | 2019 | 554 | 0.270 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 746 | 0.270 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2008 | 216 | 0.270 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2019 | 95 | 0.270 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2020 | 2183 | 0.270 |
Why?
|
| Drug Interactions | 4 | 2020 | 1419 | 0.270 |
Why?
|
| Cross Infection | 1 | 2015 | 1426 | 0.260 |
Why?
|
| Imidazoles | 2 | 2012 | 1169 | 0.260 |
Why?
|
| Replicon | 4 | 2011 | 35 | 0.260 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2018 | 281 | 0.260 |
Why?
|
| Heptanoic Acids | 2 | 2010 | 344 | 0.260 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 15645 | 0.260 |
Why?
|
| Health Care Costs | 6 | 2018 | 3239 | 0.260 |
Why?
|
| Transplantation, Homologous | 6 | 2016 | 4838 | 0.260 |
Why?
|
| United States | 43 | 2024 | 72971 | 0.260 |
Why?
|
| HIV Envelope Protein gp120 | 2 | 2024 | 923 | 0.260 |
Why?
|
| Gastrointestinal Diseases | 1 | 2014 | 1205 | 0.250 |
Why?
|
| Anabolic Agents | 1 | 2008 | 256 | 0.250 |
Why?
|
| Shoulder Joint | 1 | 2012 | 745 | 0.250 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2018 | 429 | 0.250 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2008 | 173 | 0.250 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 1403 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2021 | 5693 | 0.250 |
Why?
|
| GTP-Binding Proteins | 3 | 2019 | 946 | 0.240 |
Why?
|
| Epitopes, T-Lymphocyte | 11 | 2012 | 827 | 0.240 |
Why?
|
| Hemochromatosis | 1 | 2006 | 175 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 7 | 2018 | 5537 | 0.240 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2008 | 4572 | 0.240 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 13650 | 0.240 |
Why?
|
| Esophageal and Gastric Varices | 4 | 2019 | 215 | 0.240 |
Why?
|
| Psoriasis | 2 | 2024 | 925 | 0.240 |
Why?
|
| Candidiasis | 2 | 2021 | 366 | 0.240 |
Why?
|
| Donor Selection | 4 | 2019 | 242 | 0.240 |
Why?
|
| Diethylnitrosamine | 3 | 2024 | 45 | 0.230 |
Why?
|
| Disease Models, Animal | 15 | 2024 | 18330 | 0.230 |
Why?
|
| Hepatitis B Antibodies | 3 | 2022 | 156 | 0.230 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1433 | 0.230 |
Why?
|
| Polymorphism, Genetic | 3 | 2012 | 4247 | 0.230 |
Why?
|
| Genome-Wide Association Study | 9 | 2024 | 12790 | 0.230 |
Why?
|
| Inflammation | 9 | 2023 | 10869 | 0.230 |
Why?
|
| Comorbidity | 11 | 2020 | 10582 | 0.230 |
Why?
|
| Drug Combinations | 5 | 2020 | 2086 | 0.230 |
Why?
|
| Cognition | 1 | 2022 | 7059 | 0.230 |
Why?
|
| Cholestasis, Intrahepatic | 2 | 2002 | 75 | 0.230 |
Why?
|
| RNA | 6 | 2023 | 2715 | 0.230 |
Why?
|
| Graft Rejection | 7 | 2017 | 4498 | 0.230 |
Why?
|
| Capsules | 2 | 2022 | 193 | 0.230 |
Why?
|
| Viral Proteins | 9 | 2016 | 1801 | 0.230 |
Why?
|
| Diagnosis, Differential | 10 | 2021 | 12986 | 0.230 |
Why?
|
| Multivariate Analysis | 16 | 2019 | 12069 | 0.230 |
Why?
|
| Steroids | 2 | 2009 | 937 | 0.230 |
Why?
|
| Antigens, Viral | 3 | 2021 | 994 | 0.230 |
Why?
|
| Oxidative Stress | 5 | 2016 | 3139 | 0.220 |
Why?
|
| Young Adult | 32 | 2024 | 59980 | 0.220 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2010 | 1065 | 0.220 |
Why?
|
| Obesity | 10 | 2022 | 13085 | 0.220 |
Why?
|
| Peptide Fragments | 4 | 2012 | 5141 | 0.220 |
Why?
|
| Knee Joint | 1 | 2012 | 1683 | 0.220 |
Why?
|
| Secondary Prevention | 3 | 2020 | 1472 | 0.220 |
Why?
|
| Substance Abuse, Intravenous | 5 | 2009 | 530 | 0.220 |
Why?
|
| Guideline Adherence | 1 | 2014 | 2232 | 0.220 |
Why?
|
| Remission, Spontaneous | 7 | 2022 | 384 | 0.220 |
Why?
|
| Hypertension, Portal | 3 | 2019 | 229 | 0.220 |
Why?
|
| Hepatitis B Vaccines | 4 | 2020 | 178 | 0.220 |
Why?
|
| Transcription Factor CHOP | 2 | 2013 | 69 | 0.220 |
Why?
|
| Patient Readmission | 6 | 2021 | 3283 | 0.220 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 2 | 2014 | 17 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 8628 | 0.210 |
Why?
|
| Hemin | 2 | 2005 | 51 | 0.210 |
Why?
|
| Reverse Transcriptase Inhibitors | 6 | 2021 | 620 | 0.210 |
Why?
|
| Opioid-Related Disorders | 1 | 2018 | 2188 | 0.210 |
Why?
|
| Chemoprevention | 3 | 2022 | 327 | 0.210 |
Why?
|
| Risk Reduction Behavior | 3 | 2020 | 1119 | 0.210 |
Why?
|
| 2-Naphthylamine | 2 | 2021 | 20 | 0.210 |
Why?
|
| Bariatric Surgery | 1 | 2013 | 998 | 0.210 |
Why?
|
| Aged, 80 and over | 26 | 2022 | 59548 | 0.210 |
Why?
|
| Risk Assessment | 18 | 2020 | 24299 | 0.210 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2010 | 1372 | 0.210 |
Why?
|
| DNA-Directed RNA Polymerases | 2 | 2019 | 366 | 0.210 |
Why?
|
| Drug Monitoring | 1 | 2009 | 963 | 0.210 |
Why?
|
| Hepatitis C Antigens | 5 | 2008 | 34 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2021 | 20741 | 0.210 |
Why?
|
| Advance Care Planning | 2 | 2021 | 698 | 0.210 |
Why?
|
| Organophosphorus Compounds | 1 | 2004 | 209 | 0.210 |
Why?
|
| Interferon-gamma | 7 | 2021 | 3154 | 0.210 |
Why?
|
| Bone Morphogenetic Proteins | 3 | 2019 | 845 | 0.210 |
Why?
|
| Acute Disease | 12 | 2022 | 7236 | 0.210 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2003 | 137 | 0.200 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2024 | 627 | 0.200 |
Why?
|
| Glomerulonephritis | 3 | 2018 | 333 | 0.200 |
Why?
|
| Prevalence | 19 | 2022 | 15851 | 0.200 |
Why?
|
| Pilot Projects | 11 | 2021 | 8732 | 0.200 |
Why?
|
| Chronic Disease | 13 | 2024 | 9362 | 0.200 |
Why?
|
| Interferon Regulatory Factor-3 | 2 | 2022 | 146 | 0.200 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2014 | 58 | 0.200 |
Why?
|
| Weight Loss | 2 | 2017 | 2716 | 0.200 |
Why?
|
| Porphyria, Hepatoerythropoietic | 1 | 2002 | 8 | 0.200 |
Why?
|
| Gene Expression | 5 | 2022 | 7587 | 0.200 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2016 | 2843 | 0.200 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2002 | 434 | 0.200 |
Why?
|
| Base Sequence | 11 | 2016 | 12414 | 0.200 |
Why?
|
| Erythropoietin | 2 | 2020 | 718 | 0.200 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 2598 | 0.200 |
Why?
|
| Zambia | 4 | 2024 | 273 | 0.200 |
Why?
|
| Trans-Activators | 4 | 2016 | 2856 | 0.200 |
Why?
|
| Models, Biological | 5 | 2021 | 9464 | 0.200 |
Why?
|
| Drug Repositioning | 1 | 2024 | 246 | 0.200 |
Why?
|
| Palliative Care | 5 | 2021 | 3641 | 0.200 |
Why?
|
| Liver Failure | 2 | 2018 | 252 | 0.200 |
Why?
|
| Phosphorylation | 10 | 2014 | 8310 | 0.200 |
Why?
|
| Ascites | 4 | 2015 | 336 | 0.200 |
Why?
|
| High-Throughput Screening Assays | 4 | 2017 | 940 | 0.190 |
Why?
|
| Plasma Cells | 2 | 2024 | 599 | 0.190 |
Why?
|
| Isoenzymes | 2 | 2014 | 1688 | 0.190 |
Why?
|
| Adolescent | 36 | 2024 | 89046 | 0.190 |
Why?
|
| Peroxidases | 1 | 2022 | 134 | 0.190 |
Why?
|
| Pyrroles | 2 | 2010 | 1122 | 0.190 |
Why?
|
| Mice | 27 | 2024 | 81912 | 0.190 |
Why?
|
| Captopril | 1 | 2022 | 261 | 0.190 |
Why?
|
| Renal Dialysis | 4 | 2017 | 1790 | 0.190 |
Why?
|
| Frontotemporal Dementia | 1 | 2024 | 249 | 0.190 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2009 | 350 | 0.190 |
Why?
|
| Serologic Tests | 5 | 2022 | 382 | 0.190 |
Why?
|
| Transfection | 7 | 2017 | 5753 | 0.190 |
Why?
|
| Neoplasms | 3 | 2024 | 22350 | 0.190 |
Why?
|
| Viral Envelope Proteins | 1 | 2005 | 640 | 0.190 |
Why?
|
| Endovascular Procedures | 1 | 2015 | 2215 | 0.180 |
Why?
|
| Uracil | 2 | 2021 | 210 | 0.180 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2016 | 57 | 0.180 |
Why?
|
| Logistic Models | 16 | 2019 | 13284 | 0.180 |
Why?
|
| Patient Selection | 4 | 2019 | 4256 | 0.180 |
Why?
|
| Vesicular Transport Proteins | 2 | 2015 | 377 | 0.180 |
Why?
|
| Acetaminophen | 3 | 2014 | 549 | 0.180 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2022 | 220 | 0.180 |
Why?
|
| Information Literacy | 1 | 2020 | 11 | 0.180 |
Why?
|
| Acid Ceramidase | 1 | 2020 | 21 | 0.180 |
Why?
|
| Creatinine | 5 | 2019 | 1916 | 0.180 |
Why?
|
| Cyclophilins | 2 | 2012 | 47 | 0.180 |
Why?
|
| Incidence | 17 | 2023 | 21526 | 0.180 |
Why?
|
| Hyperbilirubinemia | 1 | 2000 | 74 | 0.180 |
Why?
|
| BK Virus | 1 | 2021 | 120 | 0.180 |
Why?
|
| Hep G2 Cells | 5 | 2024 | 378 | 0.180 |
Why?
|
| Gene Regulatory Networks | 4 | 2017 | 1752 | 0.180 |
Why?
|
| Reproducibility of Results | 11 | 2024 | 20169 | 0.180 |
Why?
|
| Tracheostomy | 1 | 2005 | 430 | 0.180 |
Why?
|
| Body Mass Index | 12 | 2021 | 13048 | 0.180 |
Why?
|
| Lipoproteins, HDL | 2 | 2016 | 679 | 0.180 |
Why?
|
| Adenine | 2 | 2018 | 995 | 0.170 |
Why?
|
| Proportional Hazards Models | 9 | 2021 | 12536 | 0.170 |
Why?
|
| Macrophages | 7 | 2022 | 5785 | 0.170 |
Why?
|
| Proteomics | 3 | 2023 | 3913 | 0.170 |
Why?
|
| Epigenesis, Genetic | 5 | 2024 | 3828 | 0.170 |
Why?
|
| Hospital Mortality | 3 | 2022 | 5345 | 0.170 |
Why?
|
| History, 20th Century | 2 | 2021 | 2765 | 0.170 |
Why?
|
| Anticholesteremic Agents | 2 | 2018 | 969 | 0.170 |
Why?
|
| Bone Morphogenetic Protein 6 | 2 | 2018 | 58 | 0.170 |
Why?
|
| Gene Knockout Techniques | 3 | 2022 | 804 | 0.170 |
Why?
|
| Digestive System Diseases | 1 | 2021 | 152 | 0.170 |
Why?
|
| Bile Acids and Salts | 1 | 2022 | 398 | 0.170 |
Why?
|
| Prednisone | 2 | 2005 | 1566 | 0.170 |
Why?
|
| Treatment Failure | 4 | 2014 | 2658 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2021 | 208 | 0.170 |
Why?
|
| HMGB1 Protein | 1 | 2021 | 140 | 0.170 |
Why?
|
| Oligonucleotides | 3 | 2020 | 561 | 0.170 |
Why?
|
| Pharmacogenetics | 3 | 2011 | 682 | 0.170 |
Why?
|
| Flavanones | 2 | 2011 | 75 | 0.170 |
Why?
|
| Massachusetts | 7 | 2019 | 8890 | 0.170 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2020 | 102 | 0.170 |
Why?
|
| RNA Viruses | 1 | 2020 | 110 | 0.170 |
Why?
|
| Lactulose | 1 | 2019 | 30 | 0.160 |
Why?
|
| Polyomavirus Infections | 1 | 2021 | 192 | 0.160 |
Why?
|
| Anti-HIV Agents | 7 | 2024 | 4567 | 0.160 |
Why?
|
| Cross-Sectional Studies | 17 | 2023 | 26325 | 0.160 |
Why?
|
| Lymphocyte Activation | 7 | 2024 | 5499 | 0.160 |
Why?
|
| Continuity of Patient Care | 2 | 2024 | 1078 | 0.160 |
Why?
|
| Esophageal Diseases | 1 | 2000 | 167 | 0.160 |
Why?
|
| Alkaline Phosphatase | 1 | 2022 | 861 | 0.160 |
Why?
|
| Transferrin | 1 | 2020 | 283 | 0.160 |
Why?
|
| Genomics | 3 | 2024 | 5924 | 0.160 |
Why?
|
| Myofibroblasts | 3 | 2017 | 230 | 0.160 |
Why?
|
| Contrast Media | 1 | 2012 | 5329 | 0.160 |
Why?
|
| Amino Acid Substitution | 3 | 2022 | 1743 | 0.160 |
Why?
|
| Overweight | 2 | 2021 | 2448 | 0.160 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2022 | 1939 | 0.160 |
Why?
|
| Immunohistochemistry | 9 | 2021 | 11063 | 0.160 |
Why?
|
| Pyrrolidines | 3 | 2020 | 339 | 0.160 |
Why?
|
| Ulcer | 1 | 2000 | 203 | 0.160 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2005 | 788 | 0.160 |
Why?
|
| Growth Substances | 1 | 2021 | 759 | 0.160 |
Why?
|
| Mutation | 16 | 2021 | 30211 | 0.160 |
Why?
|
| Biopsy, Needle | 6 | 2020 | 1615 | 0.160 |
Why?
|
| Serine Proteases | 2 | 2016 | 44 | 0.160 |
Why?
|
| Tumor Virus Infections | 1 | 2021 | 437 | 0.160 |
Why?
|
| GB virus C | 2 | 2010 | 9 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2020 | 2586 | 0.160 |
Why?
|
| Kidney Diseases | 3 | 2019 | 2099 | 0.160 |
Why?
|
| Gap Junctions | 1 | 2020 | 230 | 0.150 |
Why?
|
| Th2 Cells | 1 | 2024 | 1077 | 0.150 |
Why?
|
| STAT2 Transcription Factor | 2 | 2010 | 27 | 0.150 |
Why?
|
| Hexokinase | 1 | 1999 | 124 | 0.150 |
Why?
|
| Immunity | 2 | 2023 | 1002 | 0.150 |
Why?
|
| Receptors, KIR | 2 | 2009 | 114 | 0.150 |
Why?
|
| Longitudinal Studies | 12 | 2024 | 14766 | 0.150 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 6573 | 0.150 |
Why?
|
| Major Histocompatibility Complex | 2 | 2018 | 879 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2024 | 18063 | 0.150 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 2018 | 30 | 0.150 |
Why?
|
| Chemokines | 2 | 2021 | 963 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 14 | 2024 | 22361 | 0.150 |
Why?
|
| Epitopes | 4 | 2021 | 2526 | 0.150 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 1320 | 0.150 |
Why?
|
| Nucleotidyltransferases | 1 | 2020 | 242 | 0.150 |
Why?
|
| Genes, Regulator | 1 | 2019 | 373 | 0.150 |
Why?
|
| Gene Frequency | 5 | 2018 | 3621 | 0.150 |
Why?
|
| Thinness | 1 | 2021 | 482 | 0.150 |
Why?
|
| Viruses | 2 | 2015 | 371 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2020 | 2902 | 0.150 |
Why?
|
| Alleles | 7 | 2022 | 6893 | 0.150 |
Why?
|
| Peptides, Cyclic | 1 | 2020 | 390 | 0.150 |
Why?
|
| Molecular Sequence Data | 12 | 2015 | 17608 | 0.150 |
Why?
|
| Adiposity | 4 | 2021 | 1894 | 0.140 |
Why?
|
| Candida albicans | 1 | 2021 | 376 | 0.140 |
Why?
|
| Hepatitis, Viral, Human | 2 | 2010 | 141 | 0.140 |
Why?
|
| Adenoma | 1 | 2008 | 2155 | 0.140 |
Why?
|
| Cell Proliferation | 7 | 2024 | 10455 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 1604 | 0.140 |
Why?
|
| Pandemics | 4 | 2022 | 8736 | 0.140 |
Why?
|
| Induced Pluripotent Stem Cells | 6 | 2010 | 1882 | 0.140 |
Why?
|
| RNA, Messenger | 6 | 2017 | 12793 | 0.140 |
Why?
|
| Computational Biology | 3 | 2021 | 3567 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 3797 | 0.140 |
Why?
|
| Activins | 1 | 2018 | 211 | 0.140 |
Why?
|
| Hepatitis A | 1 | 2017 | 126 | 0.140 |
Why?
|
| Gene Silencing | 3 | 2016 | 1505 | 0.140 |
Why?
|
| Triglycerides | 4 | 2021 | 2444 | 0.140 |
Why?
|
| B-Lymphocytes | 2 | 2024 | 4787 | 0.140 |
Why?
|
| RNA Interference | 3 | 2016 | 2829 | 0.140 |
Why?
|
| Immunity, Cellular | 4 | 2014 | 1560 | 0.140 |
Why?
|
| Metformin | 2 | 2016 | 908 | 0.140 |
Why?
|
| Genome, Viral | 4 | 2012 | 673 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 6513 | 0.130 |
Why?
|
| Cholesterol | 4 | 2015 | 2905 | 0.130 |
Why?
|
| Receptors, CCR5 | 2 | 2010 | 491 | 0.130 |
Why?
|
| Ritonavir | 2 | 2021 | 331 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 1 | 2021 | 872 | 0.130 |
Why?
|
| Indazoles | 1 | 2018 | 306 | 0.130 |
Why?
|
| Ribonucleoproteins | 1 | 1999 | 358 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2022 | 832 | 0.130 |
Why?
|
| Pneumothorax | 1 | 2020 | 393 | 0.130 |
Why?
|
| Intensive Care Units | 3 | 2022 | 3797 | 0.130 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2016 | 31 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-jun | 3 | 2013 | 287 | 0.130 |
Why?
|
| Pyruvate Kinase | 1 | 2018 | 191 | 0.130 |
Why?
|
| Amantadine | 2 | 2009 | 58 | 0.130 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2007 | 1362 | 0.130 |
Why?
|
| Stem Cells | 3 | 2016 | 3535 | 0.130 |
Why?
|
| Cells, Cultured | 7 | 2020 | 18989 | 0.130 |
Why?
|
| Respiratory Insufficiency | 1 | 2005 | 1240 | 0.130 |
Why?
|
| Drug Discovery | 2 | 2021 | 1068 | 0.130 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2017 | 265 | 0.130 |
Why?
|
| Quality Improvement | 2 | 2022 | 3854 | 0.130 |
Why?
|
| Valine | 2 | 2021 | 410 | 0.130 |
Why?
|
| Radiology, Interventional | 1 | 2020 | 483 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2020 | 1126 | 0.130 |
Why?
|
| Ceramides | 1 | 2017 | 202 | 0.130 |
Why?
|
| Blood Proteins | 1 | 2021 | 1190 | 0.130 |
Why?
|
| Health Personnel | 1 | 2009 | 3387 | 0.130 |
Why?
|
| Nephrology | 1 | 2019 | 270 | 0.130 |
Why?
|
| Lipoproteins, VLDL | 2 | 2013 | 198 | 0.120 |
Why?
|
| alpha-Fetoproteins | 3 | 2021 | 229 | 0.120 |
Why?
|
| Antibodies, Neutralizing | 2 | 2024 | 2011 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 2457 | 0.120 |
Why?
|
| Clusterin | 1 | 2015 | 72 | 0.120 |
Why?
|
| Dental Caries | 1 | 2019 | 429 | 0.120 |
Why?
|
| Length of Stay | 2 | 2020 | 6489 | 0.120 |
Why?
|
| Point-of-Care Systems | 1 | 2024 | 1217 | 0.120 |
Why?
|
| Tantalum | 1 | 2015 | 54 | 0.120 |
Why?
|
| Heart | 2 | 2019 | 4429 | 0.120 |
Why?
|
| Antigens, CD | 3 | 2018 | 4032 | 0.120 |
Why?
|
| Pelvic Infection | 1 | 2014 | 12 | 0.120 |
Why?
|
| Proteinuria | 2 | 2017 | 613 | 0.120 |
Why?
|
| Amino Acid Sequence | 9 | 2015 | 13411 | 0.120 |
Why?
|
| Single-Cell Analysis | 2 | 2024 | 2538 | 0.120 |
Why?
|
| Anemia | 1 | 2004 | 1514 | 0.120 |
Why?
|
| Structure-Activity Relationship | 6 | 2013 | 3052 | 0.120 |
Why?
|
| Sensitivity and Specificity | 8 | 2020 | 14672 | 0.120 |
Why?
|
| Epitopes, B-Lymphocyte | 1 | 2015 | 85 | 0.120 |
Why?
|
| Protoporphyria, Erythropoietic | 2 | 2005 | 54 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2016 | 3804 | 0.120 |
Why?
|
| Enzyme Activation | 3 | 2016 | 3587 | 0.120 |
Why?
|
| Double-Blind Method | 8 | 2024 | 12451 | 0.120 |
Why?
|
| HLA Antigens | 4 | 2009 | 1334 | 0.120 |
Why?
|
| Vitamin E | 1 | 2019 | 872 | 0.120 |
Why?
|
| Cholesterol, HDL | 3 | 2015 | 1816 | 0.120 |
Why?
|
| Apolipoproteins | 1 | 2016 | 328 | 0.120 |
Why?
|
| RNA Polymerase II | 1 | 1999 | 549 | 0.120 |
Why?
|
| Lectins | 1 | 2016 | 490 | 0.120 |
Why?
|
| Polyvinyls | 1 | 2015 | 153 | 0.120 |
Why?
|
| Cytosol | 1 | 2017 | 885 | 0.120 |
Why?
|
| Adipose Tissue | 2 | 2021 | 3324 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2024 | 1804 | 0.110 |
Why?
|
| Pancreatitis | 2 | 2009 | 1087 | 0.110 |
Why?
|
| Lysophospholipids | 1 | 2016 | 336 | 0.110 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 719 | 0.110 |
Why?
|
| Attitude | 1 | 2019 | 769 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2017 | 748 | 0.110 |
Why?
|
| Receptors, CXCR4 | 2 | 2010 | 729 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2020 | 684 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2006 | 663 | 0.110 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2017 | 336 | 0.110 |
Why?
|
| Kinetics | 3 | 2016 | 6287 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2019 | 903 | 0.110 |
Why?
|
| Opiate Substitution Treatment | 1 | 2018 | 452 | 0.110 |
Why?
|
| Platelet Count | 4 | 2019 | 784 | 0.110 |
Why?
|
| Oral Health | 1 | 2019 | 493 | 0.110 |
Why?
|
| Apolipoproteins B | 2 | 2022 | 385 | 0.110 |
Why?
|
| Caspase 8 | 1 | 2014 | 198 | 0.110 |
Why?
|
| Neutrophils | 2 | 2021 | 3779 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11872 | 0.110 |
Why?
|
| Occupational Health | 1 | 2020 | 812 | 0.110 |
Why?
|
| False Positive Reactions | 1 | 2016 | 959 | 0.110 |
Why?
|
| Nucleosides | 1 | 2014 | 130 | 0.110 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2024 | 1481 | 0.110 |
Why?
|
| Family Health | 1 | 2018 | 1254 | 0.110 |
Why?
|
| Immunoassay | 2 | 2015 | 744 | 0.110 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2020 | 1458 | 0.110 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1994 | 149 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2018 | 949 | 0.110 |
Why?
|
| Nasal Cavity | 1 | 2015 | 310 | 0.110 |
Why?
|
| Protein Binding | 4 | 2012 | 9327 | 0.110 |
Why?
|
| NAD | 1 | 2017 | 618 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 2002 | 1065 | 0.110 |
Why?
|
| Immune System | 2 | 2016 | 799 | 0.110 |
Why?
|
| Rats | 9 | 2024 | 23713 | 0.110 |
Why?
|
| Benzopyrans | 1 | 2013 | 63 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2020 | 1271 | 0.110 |
Why?
|
| Immunoglobulin G | 3 | 2014 | 4560 | 0.110 |
Why?
|
| Hepatitis D | 1 | 1993 | 23 | 0.110 |
Why?
|
| Telemedicine | 2 | 2020 | 3110 | 0.100 |
Why?
|
| Bacterial Translocation | 1 | 2013 | 74 | 0.100 |
Why?
|
| Collagen | 2 | 2022 | 2636 | 0.100 |
Why?
|
| Receptors, LDL | 1 | 2015 | 492 | 0.100 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2016 | 1366 | 0.100 |
Why?
|
| Transcription, Genetic | 4 | 2017 | 7611 | 0.100 |
Why?
|
| Circadian Rhythm | 1 | 2024 | 2591 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2008 | 4349 | 0.100 |
Why?
|
| Interleukin-10 | 4 | 2008 | 1182 | 0.100 |
Why?
|
| Coffee | 1 | 2017 | 594 | 0.100 |
Why?
|
| Desmosterol | 1 | 2012 | 3 | 0.100 |
Why?
|
| Hospice Care | 1 | 2019 | 678 | 0.100 |
Why?
|
| Bacteremia | 1 | 2019 | 983 | 0.100 |
Why?
|
| Coculture Techniques | 1 | 2016 | 1337 | 0.100 |
Why?
|
| Substance-Related Disorders | 2 | 2008 | 4422 | 0.100 |
Why?
|
| Models, Molecular | 3 | 2019 | 5388 | 0.100 |
Why?
|
| Radiography, Interventional | 1 | 2020 | 1129 | 0.100 |
Why?
|
| Antithrombin III | 1 | 2012 | 128 | 0.100 |
Why?
|
| Hematoma | 1 | 2017 | 766 | 0.100 |
Why?
|
| New England | 2 | 2013 | 1058 | 0.100 |
Why?
|
| Pyrazines | 1 | 2018 | 1204 | 0.100 |
Why?
|
| Fatal Outcome | 3 | 2019 | 1836 | 0.100 |
Why?
|
| Case-Control Studies | 9 | 2021 | 22254 | 0.100 |
Why?
|
| Blotting, Western | 4 | 2016 | 5022 | 0.100 |
Why?
|
| Quality of Life | 6 | 2024 | 13485 | 0.100 |
Why?
|
| Infectious Disease Medicine | 1 | 2012 | 49 | 0.100 |
Why?
|
| Body Weight | 3 | 2012 | 4627 | 0.100 |
Why?
|
| Marital Status | 1 | 2013 | 426 | 0.100 |
Why?
|
| ROC Curve | 3 | 2018 | 3618 | 0.100 |
Why?
|
| Blood Glucose | 3 | 2021 | 6421 | 0.100 |
Why?
|
| Administration, Oral | 5 | 2019 | 4026 | 0.100 |
Why?
|
| Receptors, Immunologic | 2 | 2015 | 1418 | 0.100 |
Why?
|
| Hospitalization | 6 | 2024 | 10815 | 0.100 |
Why?
|
| Hepatitis Antibodies | 2 | 2010 | 67 | 0.090 |
Why?
|
| Early Diagnosis | 2 | 2016 | 1188 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2018 | 1331 | 0.090 |
Why?
|
| Deoxyribonucleases | 1 | 2012 | 209 | 0.090 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 296 | 0.090 |
Why?
|
| Necrosis | 2 | 2023 | 1614 | 0.090 |
Why?
|
| Biosensing Techniques | 1 | 2017 | 641 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 2270 | 0.090 |
Why?
|
| Referral and Consultation | 3 | 2019 | 3618 | 0.090 |
Why?
|
| Cell Separation | 1 | 2017 | 1717 | 0.090 |
Why?
|
| Clostridium Infections | 1 | 2018 | 562 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2021 | 1604 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 3 | 2007 | 9245 | 0.090 |
Why?
|
| Drug Eruptions | 1 | 2014 | 335 | 0.090 |
Why?
|
| Phylogeny | 6 | 2008 | 2840 | 0.090 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2019 | 996 | 0.090 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2011 | 113 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 3 | 2024 | 1131 | 0.090 |
Why?
|
| Autophagy | 1 | 2019 | 1347 | 0.090 |
Why?
|
| Florida | 1 | 2012 | 417 | 0.090 |
Why?
|
| TYK2 Kinase | 1 | 2010 | 38 | 0.090 |
Why?
|
| Immunization | 1 | 2015 | 1218 | 0.090 |
Why?
|
| Caspase 7 | 1 | 2010 | 51 | 0.090 |
Why?
|
| GTPase-Activating Proteins | 1 | 2014 | 467 | 0.090 |
Why?
|
| Appendectomy | 1 | 2014 | 444 | 0.090 |
Why?
|
| Pancreatic Diseases | 1 | 1993 | 354 | 0.090 |
Why?
|
| Abscess | 1 | 2014 | 606 | 0.090 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2012 | 174 | 0.090 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 460 | 0.090 |
Why?
|
| Nutritional Status | 1 | 2019 | 1628 | 0.090 |
Why?
|
| Syndrome | 1 | 2017 | 3271 | 0.090 |
Why?
|
| Janus Kinase 1 | 1 | 2010 | 108 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 2 | 2019 | 1604 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2013 | 582 | 0.090 |
Why?
|
| Receptors, Interferon | 1 | 2010 | 115 | 0.090 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2010 | 88 | 0.090 |
Why?
|
| Virus Assembly | 1 | 2011 | 140 | 0.090 |
Why?
|
| Genes, Reporter | 2 | 2017 | 1526 | 0.090 |
Why?
|
| Flaviviridae Infections | 1 | 2010 | 7 | 0.090 |
Why?
|
| Chromatography, Affinity | 1 | 2011 | 524 | 0.090 |
Why?
|
| Alcoholism | 1 | 2021 | 1980 | 0.090 |
Why?
|
| Patient Discharge | 2 | 2020 | 3467 | 0.090 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2013 | 214 | 0.090 |
Why?
|
| Diuretics | 1 | 2013 | 614 | 0.090 |
Why?
|
| Anti-Ulcer Agents | 1 | 2011 | 112 | 0.090 |
Why?
|
| Energy Metabolism | 2 | 2020 | 2906 | 0.090 |
Why?
|
| Drug Therapy | 1 | 2013 | 504 | 0.090 |
Why?
|
| Zidovudine | 2 | 2007 | 625 | 0.090 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2010 | 69 | 0.090 |
Why?
|
| Crohn Disease | 2 | 2018 | 2295 | 0.090 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 2012 | 0.090 |
Why?
|
| Cytochromes c | 1 | 2010 | 173 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1991 | 418 | 0.080 |
Why?
|
| Sex Factors | 2 | 2021 | 10622 | 0.080 |
Why?
|
| Up-Regulation | 5 | 2023 | 4143 | 0.080 |
Why?
|
| RNA-Binding Proteins | 1 | 1999 | 1889 | 0.080 |
Why?
|
| Bilirubin | 3 | 2012 | 440 | 0.080 |
Why?
|
| Quinolines | 3 | 2010 | 770 | 0.080 |
Why?
|
| Bacteria | 1 | 2021 | 2212 | 0.080 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2010 | 151 | 0.080 |
Why?
|
| Mice, Knockout | 7 | 2021 | 14476 | 0.080 |
Why?
|
| Attitude to Health | 1 | 2018 | 2023 | 0.080 |
Why?
|
| Canada | 3 | 2020 | 2127 | 0.080 |
Why?
|
| Autoimmune Diseases | 2 | 2014 | 2255 | 0.080 |
Why?
|
| Blood-Borne Pathogens | 1 | 2009 | 52 | 0.080 |
Why?
|
| Sugar Alcohol Dehydrogenases | 1 | 2009 | 12 | 0.080 |
Why?
|
| Ventricular Remodeling | 1 | 2017 | 1281 | 0.080 |
Why?
|
| Prediabetic State | 1 | 2015 | 547 | 0.080 |
Why?
|
| Ultrasonography | 3 | 2016 | 6000 | 0.080 |
Why?
|
| Immunity, Active | 1 | 2009 | 58 | 0.080 |
Why?
|
| Capsid Proteins | 1 | 2012 | 468 | 0.080 |
Why?
|
| Genes, MHC Class II | 2 | 2008 | 433 | 0.080 |
Why?
|
| Age Factors | 7 | 2022 | 18401 | 0.080 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 2007 | 152 | 0.080 |
Why?
|
| Needlestick Injuries | 1 | 2009 | 71 | 0.080 |
Why?
|
| Mortality | 1 | 2020 | 2909 | 0.080 |
Why?
|
| Viral Interference | 1 | 2008 | 11 | 0.080 |
Why?
|
| Coat Protein Complex I | 1 | 2009 | 37 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 13491 | 0.080 |
Why?
|
| Databases, Factual | 7 | 2019 | 8068 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 330 | 0.080 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 2815 | 0.080 |
Why?
|
| Virus Diseases | 1 | 2015 | 722 | 0.080 |
Why?
|
| Survival Rate | 7 | 2024 | 12823 | 0.080 |
Why?
|
| Adiponectin | 1 | 2015 | 1115 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 2337 | 0.080 |
Why?
|
| Inflammation Mediators | 2 | 2021 | 1889 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 1119 | 0.080 |
Why?
|
| Graft Survival | 3 | 2016 | 3896 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2014 | 754 | 0.080 |
Why?
|
| Embolism, Air | 1 | 2009 | 111 | 0.080 |
Why?
|
| Vitamin D | 2 | 2013 | 3312 | 0.080 |
Why?
|
| Diagnostic Techniques, Digestive System | 1 | 2008 | 45 | 0.080 |
Why?
|
| Hypertension | 1 | 2009 | 8615 | 0.080 |
Why?
|
| Drainage | 1 | 2014 | 1183 | 0.080 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2010 | 428 | 0.080 |
Why?
|
| Heart Transplantation | 2 | 2019 | 3305 | 0.080 |
Why?
|
| Thiazoles | 2 | 2013 | 1530 | 0.080 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 3928 | 0.080 |
Why?
|
| Oleanolic Acid | 1 | 2008 | 43 | 0.080 |
Why?
|
| Cholangitis | 1 | 2009 | 110 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 4054 | 0.080 |
Why?
|
| Gastric Bypass | 1 | 2017 | 820 | 0.080 |
Why?
|
| DNA, Mitochondrial | 1 | 2013 | 872 | 0.080 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 3414 | 0.080 |
Why?
|
| Phenotype | 6 | 2021 | 16718 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 4892 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2010 | 730 | 0.080 |
Why?
|
| Sequence Alignment | 3 | 2007 | 2176 | 0.080 |
Why?
|
| Medicare | 2 | 2017 | 6813 | 0.070 |
Why?
|
| Drosophila Proteins | 1 | 2017 | 1705 | 0.070 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2008 | 47 | 0.070 |
Why?
|
| Antibodies | 2 | 2008 | 2419 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2011 | 484 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 1646 | 0.070 |
Why?
|
| Nucleotides | 1 | 2010 | 454 | 0.070 |
Why?
|
| Virus Integration | 1 | 2010 | 307 | 0.070 |
Why?
|
| Amyloidosis | 1 | 2015 | 876 | 0.070 |
Why?
|
| Appendicitis | 1 | 2014 | 679 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2014 | 1574 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2010 | 1606 | 0.070 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2009 | 303 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 9612 | 0.070 |
Why?
|
| Preoperative Care | 1 | 2017 | 2252 | 0.070 |
Why?
|
| Mass Spectrometry | 2 | 2013 | 2201 | 0.070 |
Why?
|
| Fas Ligand Protein | 1 | 2008 | 216 | 0.070 |
Why?
|
| Algorithms | 4 | 2017 | 14098 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2017 | 6331 | 0.070 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2005 | 976 | 0.070 |
Why?
|
| Child | 11 | 2024 | 80771 | 0.070 |
Why?
|
| Mice, Nude | 1 | 2014 | 3618 | 0.070 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 616 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 1405 | 0.070 |
Why?
|
| Escherichia coli | 1 | 2019 | 4209 | 0.070 |
Why?
|
| Maleimides | 1 | 2007 | 112 | 0.070 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 6550 | 0.070 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2019 | 2764 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1991 | 1058 | 0.070 |
Why?
|
| Survival Analysis | 5 | 2021 | 10092 | 0.070 |
Why?
|
| Astrocytoma | 1 | 1991 | 773 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 1492 | 0.070 |
Why?
|
| Phosphoproteins | 1 | 2015 | 2448 | 0.070 |
Why?
|
| Chromosome Deletion | 1 | 1991 | 1384 | 0.070 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 434 | 0.070 |
Why?
|
| Sweden | 2 | 2020 | 1382 | 0.070 |
Why?
|
| Waist Circumference | 2 | 2021 | 935 | 0.070 |
Why?
|
| Portal Vein | 1 | 2009 | 437 | 0.070 |
Why?
|
| Placebos | 2 | 2021 | 1660 | 0.070 |
Why?
|
| Epithelial Cells | 1 | 2018 | 3698 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2018 | 1741 | 0.070 |
Why?
|
| Glucocorticoids | 3 | 2005 | 2163 | 0.070 |
Why?
|
| Coccidioides | 1 | 2006 | 17 | 0.070 |
Why?
|
| Epitope Mapping | 1 | 2007 | 301 | 0.070 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 268 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 10 | 1 | 2005 | 9 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2017 | 1945 | 0.060 |
Why?
|
| Gene Products, env | 1 | 2007 | 250 | 0.060 |
Why?
|
| Brain | 2 | 2012 | 27163 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2015 | 1761 | 0.060 |
Why?
|
| Coccidioidomycosis | 1 | 2006 | 36 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 1293 | 0.060 |
Why?
|
| Pentylenetetrazole | 1 | 2005 | 72 | 0.060 |
Why?
|
| Phlebotomy | 1 | 2006 | 138 | 0.060 |
Why?
|
| Convulsants | 1 | 2005 | 70 | 0.060 |
Why?
|
| Hepatectomy | 2 | 2009 | 589 | 0.060 |
Why?
|
| Review Literature as Topic | 2 | 2017 | 297 | 0.060 |
Why?
|
| Obesity, Abdominal | 2 | 2021 | 373 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 588 | 0.060 |
Why?
|
| Hematologic Tests | 1 | 2006 | 239 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 3266 | 0.060 |
Why?
|
| src Homology Domains | 1 | 2006 | 360 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 3611 | 0.060 |
Why?
|
| Factor V | 1 | 2006 | 168 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 5 | 2021 | 4780 | 0.060 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2005 | 147 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2018 | 12250 | 0.060 |
Why?
|
| HLA-DR Antigens | 2 | 2005 | 609 | 0.060 |
Why?
|
| HLA-B8 Antigen | 1 | 2004 | 16 | 0.060 |
Why?
|
| Viral Hepatitis Vaccines | 2 | 2017 | 72 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 2883 | 0.060 |
Why?
|
| Life Style | 1 | 2017 | 3931 | 0.060 |
Why?
|
| Health Services Accessibility | 2 | 2024 | 5519 | 0.060 |
Why?
|
| Thioacetamide | 1 | 2024 | 22 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 3667 | 0.060 |
Why?
|
| Europe | 3 | 2017 | 3432 | 0.060 |
Why?
|
| Protein Disulfide-Isomerases | 1 | 2007 | 209 | 0.060 |
Why?
|
| Depression | 2 | 2018 | 8234 | 0.060 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2005 | 59 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2020 | 3464 | 0.060 |
Why?
|
| Proviruses | 1 | 2006 | 319 | 0.060 |
Why?
|
| Small Molecule Libraries | 1 | 2010 | 742 | 0.060 |
Why?
|
| Stomach Diseases | 1 | 2006 | 134 | 0.060 |
Why?
|
| Disulfides | 1 | 2007 | 462 | 0.060 |
Why?
|
| Survivors | 2 | 2014 | 2381 | 0.060 |
Why?
|
| Nutrition Surveys | 1 | 2012 | 1738 | 0.060 |
Why?
|
| Carbon Tetrachloride | 1 | 2024 | 72 | 0.060 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2004 | 2204 | 0.060 |
Why?
|
| Dioxoles | 1 | 2005 | 96 | 0.060 |
Why?
|
| Inpatients | 1 | 2016 | 2563 | 0.060 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2005 | 130 | 0.060 |
Why?
|
| Immunodominant Epitopes | 1 | 2005 | 244 | 0.060 |
Why?
|
| Riluzole | 1 | 2024 | 62 | 0.060 |
Why?
|
| Vascular Resistance | 1 | 2007 | 939 | 0.060 |
Why?
|
| Parents | 1 | 2018 | 3594 | 0.060 |
Why?
|
| Needs Assessment | 2 | 2020 | 1141 | 0.060 |
Why?
|
| Immunosuppressive Agents | 3 | 2008 | 4210 | 0.060 |
Why?
|
| Registries | 5 | 2020 | 8351 | 0.060 |
Why?
|
| DNA Repeat Expansion | 1 | 2024 | 74 | 0.060 |
Why?
|
| Lignans | 1 | 2005 | 83 | 0.060 |
Why?
|
| Public Health | 2 | 2020 | 2681 | 0.060 |
Why?
|
| Benzofurans | 1 | 2005 | 139 | 0.060 |
Why?
|
| IMP Dehydrogenase | 1 | 2004 | 34 | 0.060 |
Why?
|
| Computer Simulation | 2 | 2008 | 6260 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2016 | 2191 | 0.060 |
Why?
|
| Organ Specificity | 2 | 2021 | 1966 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 3370 | 0.060 |
Why?
|
| Peptides | 3 | 2021 | 4348 | 0.060 |
Why?
|
| Anilides | 2 | 2021 | 413 | 0.060 |
Why?
|
| Naphthalenes | 1 | 2005 | 198 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 3212 | 0.050 |
Why?
|
| Homeostasis | 3 | 2020 | 3345 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2783 | 0.050 |
Why?
|
| Cluster Analysis | 3 | 2017 | 2721 | 0.050 |
Why?
|
| Precancerous Conditions | 2 | 2017 | 980 | 0.050 |
Why?
|
| Transplantation | 1 | 2005 | 221 | 0.050 |
Why?
|
| Body Constitution | 1 | 2003 | 273 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2001 | 1801 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 3760 | 0.050 |
Why?
|
| Transcription Factors | 3 | 2017 | 12158 | 0.050 |
Why?
|
| Chromatin | 3 | 2021 | 2980 | 0.050 |
Why?
|
| Internationality | 2 | 2019 | 1006 | 0.050 |
Why?
|
| Exercise | 1 | 2020 | 5954 | 0.050 |
Why?
|
| Vena Cava, Inferior | 1 | 2006 | 463 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2010 | 2952 | 0.050 |
Why?
|
| Disease Management | 1 | 2013 | 2531 | 0.050 |
Why?
|
| DNA, Complementary | 2 | 2008 | 1989 | 0.050 |
Why?
|
| Janus Kinase 2 | 1 | 2006 | 561 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2014 | 2037 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2006 | 704 | 0.050 |
Why?
|
| Ischemia | 1 | 2011 | 1905 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2004 | 614 | 0.050 |
Why?
|
| Arthralgia | 1 | 2006 | 459 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 6106 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2824 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 2 | 2023 | 2040 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 1150 | 0.050 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 3236 | 0.050 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 1 | 2022 | 26 | 0.050 |
Why?
|
| Prednisolone | 1 | 2003 | 326 | 0.050 |
Why?
|
| Circadian Clocks | 1 | 2024 | 168 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2015 | 874 | 0.050 |
Why?
|
| Health Surveys | 1 | 2012 | 4056 | 0.050 |
Why?
|
| Area Under Curve | 3 | 2012 | 1639 | 0.050 |
Why?
|
| Nizatidine | 1 | 2021 | 7 | 0.050 |
Why?
|
| Enterocolitis | 1 | 2003 | 106 | 0.050 |
Why?
|
| Lypressin | 1 | 2021 | 26 | 0.050 |
Why?
|
| Terminator Regions, Genetic | 1 | 2001 | 26 | 0.050 |
Why?
|
| Genome, Human | 2 | 2012 | 4441 | 0.050 |
Why?
|
| Lipoproteins, LDL | 2 | 2015 | 640 | 0.050 |
Why?
|
| Micelles | 1 | 2022 | 190 | 0.050 |
Why?
|
| Developing Countries | 1 | 2014 | 2911 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2013 | 2875 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2022 | 149 | 0.050 |
Why?
|
| RNA, Catalytic | 1 | 2001 | 52 | 0.050 |
Why?
|
| HIV Core Protein p24 | 2 | 2006 | 245 | 0.050 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2021 | 64 | 0.050 |
Why?
|
| Septins | 1 | 2021 | 47 | 0.050 |
Why?
|
| Neuroprotective Agents | 2 | 2024 | 956 | 0.050 |
Why?
|
| Mycoplasma fermentans | 1 | 2000 | 9 | 0.050 |
Why?
|
| Genes, Synthetic | 1 | 2001 | 88 | 0.050 |
Why?
|
| Lung | 1 | 2020 | 10076 | 0.050 |
Why?
|
| Point Mutation | 1 | 2006 | 1591 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 3108 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2023 | 9660 | 0.050 |
Why?
|
| Immunologic Surveillance | 1 | 2021 | 92 | 0.050 |
Why?
|
| Homosexuality, Male | 1 | 2009 | 1344 | 0.050 |
Why?
|
| Living Donors | 1 | 2005 | 647 | 0.050 |
Why?
|
| Carbon Tetrachloride Poisoning | 1 | 2020 | 11 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 2061 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2012 | 6215 | 0.050 |
Why?
|
| Hyphae | 1 | 2021 | 52 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 2011 | 4925 | 0.050 |
Why?
|
| High Mobility Group Proteins | 1 | 2021 | 179 | 0.050 |
Why?
|
| Cyclohexylamines | 1 | 2020 | 21 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 461 | 0.040 |
Why?
|
| Chemokine CXCL10 | 1 | 2022 | 311 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2022 | 325 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2012 | 3431 | 0.040 |
Why?
|
| Mycoplasma Infections | 1 | 2000 | 120 | 0.040 |
Why?
|
| Propensity Score | 2 | 2019 | 1971 | 0.040 |
Why?
|
| PPAR alpha | 1 | 2021 | 177 | 0.040 |
Why?
|
| Persian Gulf Syndrome | 1 | 2000 | 48 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3608 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2005 | 1504 | 0.040 |
Why?
|
| Permeability | 1 | 2022 | 721 | 0.040 |
Why?
|
| Protein Kinases | 1 | 2007 | 1610 | 0.040 |
Why?
|
| Hypogonadism | 1 | 2006 | 805 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2007 | 2745 | 0.040 |
Why?
|
| Citrus paradisi | 2 | 2011 | 9 | 0.040 |
Why?
|
| Phenylenediamines | 1 | 2020 | 89 | 0.040 |
Why?
|
| Bacteriophage T7 | 1 | 2001 | 174 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2020 | 5947 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2022 | 384 | 0.040 |
Why?
|
| Erythrocyte Transfusion | 1 | 2005 | 575 | 0.040 |
Why?
|
| Apolipoproteins E | 2 | 2015 | 1459 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2005 | 1824 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2020 | 417 | 0.040 |
Why?
|
| Adipocytes, Brown | 1 | 2020 | 160 | 0.040 |
Why?
|
| Iron, Dietary | 1 | 2020 | 148 | 0.040 |
Why?
|
| Ligands | 2 | 2022 | 3273 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2004 | 702 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2020 | 276 | 0.040 |
Why?
|
| Nurses | 2 | 2020 | 2501 | 0.040 |
Why?
|
| Bottle Feeding | 1 | 2019 | 67 | 0.040 |
Why?
|
| Haplotypes | 2 | 2020 | 2722 | 0.040 |
Why?
|
| Fatigue | 1 | 2006 | 1556 | 0.040 |
Why?
|
| Polypyrimidine Tract-Binding Protein | 1 | 1999 | 22 | 0.040 |
Why?
|
| Platinum | 1 | 2020 | 219 | 0.040 |
Why?
|
| Singapore | 1 | 2020 | 300 | 0.040 |
Why?
|
| Pregnancy | 5 | 2020 | 30238 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2009 | 1807 | 0.040 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1999 | 62 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2007 | 3948 | 0.040 |
Why?
|
| DNA | 1 | 2013 | 7210 | 0.040 |
Why?
|
| Symporters | 1 | 2022 | 363 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2021 | 369 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 501 | 0.040 |
Why?
|
| Medication Therapy Management | 1 | 2020 | 131 | 0.040 |
Why?
|
| Hippocampus | 2 | 2015 | 3777 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 2912 | 0.040 |
Why?
|
| Smad1 Protein | 1 | 2018 | 81 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2020 | 562 | 0.040 |
Why?
|
| Taiwan | 1 | 2020 | 521 | 0.040 |
Why?
|
| Extracellular Matrix | 2 | 2017 | 1733 | 0.040 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2005 | 1319 | 0.040 |
Why?
|
| Vietnam | 1 | 2019 | 413 | 0.040 |
Why?
|
| Bone Remodeling | 1 | 2022 | 582 | 0.040 |
Why?
|
| Histone Code | 1 | 2019 | 160 | 0.040 |
Why?
|
| Heart-Lung Transplantation | 1 | 1999 | 87 | 0.040 |
Why?
|
| Atrial Fibrillation | 1 | 2017 | 5180 | 0.040 |
Why?
|
| Chicago | 1 | 2018 | 255 | 0.040 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2013 | 370 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 501 | 0.040 |
Why?
|
| Iron Overload | 1 | 2020 | 245 | 0.040 |
Why?
|
| Caregivers | 2 | 2020 | 2302 | 0.040 |
Why?
|
| Growth Hormone | 1 | 2020 | 572 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2019 | 391 | 0.040 |
Why?
|
| Immunotherapy | 3 | 2016 | 4745 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 2022 | 1617 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2004 | 1592 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2000 | 631 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 655 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2020 | 619 | 0.040 |
Why?
|
| Oxidation-Reduction | 2 | 2017 | 2221 | 0.040 |
Why?
|
| Cation Transport Proteins | 1 | 2020 | 325 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 2850 | 0.040 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 1350 | 0.040 |
Why?
|
| Cell Lineage | 2 | 2017 | 2575 | 0.040 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1998 | 82 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2006 | 1883 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2019 | 307 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 1999 | 1141 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2021 | 1472 | 0.040 |
Why?
|
| Plasmids | 3 | 2014 | 2268 | 0.040 |
Why?
|
| Efficiency | 1 | 2020 | 479 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 2023 | 873 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2018 | 271 | 0.040 |
Why?
|
| Viral Structural Proteins | 1 | 1997 | 93 | 0.030 |
Why?
|
| Regional Health Planning | 1 | 2017 | 95 | 0.030 |
Why?
|
| Remission Induction | 2 | 2019 | 2408 | 0.030 |
Why?
|
| Cause of Death | 2 | 2019 | 3717 | 0.030 |
Why?
|
| Microcirculation | 2 | 1999 | 1282 | 0.030 |
Why?
|
| Pediatrics | 1 | 2012 | 3621 | 0.030 |
Why?
|
| Fluorine Radioisotopes | 1 | 2020 | 405 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2022 | 1716 | 0.030 |
Why?
|
| COS Cells | 1 | 1999 | 1135 | 0.030 |
Why?
|
| Ethanol | 1 | 2023 | 1330 | 0.030 |
Why?
|
| Mice, Transgenic | 3 | 2005 | 9551 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2015 | 2920 | 0.030 |
Why?
|
| E-Selectin | 1 | 2019 | 576 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 587 | 0.030 |
Why?
|
| Cell Death | 2 | 2016 | 1677 | 0.030 |
Why?
|
| Azithromycin | 1 | 1998 | 201 | 0.030 |
Why?
|
| Shear Strength | 1 | 2017 | 159 | 0.030 |
Why?
|
| Erythropoiesis | 1 | 2020 | 691 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2019 | 737 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2019 | 692 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2021 | 11657 | 0.030 |
Why?
|
| Data Mining | 1 | 2021 | 561 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 11513 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2006 | 3445 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2000 | 1352 | 0.030 |
Why?
|
| Glioblastoma | 1 | 1991 | 3461 | 0.030 |
Why?
|
| Metal Nanoparticles | 1 | 2020 | 400 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 10393 | 0.030 |
Why?
|
| Elastic Modulus | 1 | 2017 | 210 | 0.030 |
Why?
|
| Species Specificity | 1 | 2020 | 2412 | 0.030 |
Why?
|
| Binding Sites | 2 | 2009 | 6014 | 0.030 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2016 | 140 | 0.030 |
Why?
|
| Atherosclerosis | 3 | 2017 | 3418 | 0.030 |
Why?
|
| Mexico | 2 | 2009 | 769 | 0.030 |
Why?
|
| Drug Synergism | 2 | 2011 | 1759 | 0.030 |
Why?
|
| Cultural Competency | 1 | 2019 | 303 | 0.030 |
Why?
|
| Thailand | 1 | 2016 | 288 | 0.030 |
Why?
|
| Antibodies, Bacterial | 2 | 2000 | 1477 | 0.030 |
Why?
|
| Rats, Inbred Lew | 1 | 2017 | 1168 | 0.030 |
Why?
|
| Rhabdomyolysis | 1 | 2017 | 150 | 0.030 |
Why?
|
| Acetylcysteine | 1 | 2017 | 262 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2016 | 190 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2020 | 2472 | 0.030 |
Why?
|
| Conserved Sequence | 1 | 1999 | 1160 | 0.030 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2015 | 118 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2018 | 456 | 0.030 |
Why?
|
| GPI-Linked Proteins | 2 | 2008 | 472 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 1999 | 899 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 1132 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 2 | 2 | 2008 | 343 | 0.030 |
Why?
|
| Child, Preschool | 4 | 2021 | 42606 | 0.030 |
Why?
|
| Mothers | 2 | 2016 | 2209 | 0.030 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2016 | 190 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2022 | 2093 | 0.030 |
Why?
|
| Radiography | 1 | 2006 | 6975 | 0.030 |
Why?
|
| Protoporphyrins | 2 | 2005 | 167 | 0.030 |
Why?
|
| Mammals | 1 | 2020 | 1135 | 0.030 |
Why?
|
| Probability | 2 | 2011 | 2476 | 0.030 |
Why?
|
| Endopeptidases | 1 | 2018 | 762 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 2020 | 1160 | 0.030 |
Why?
|
| SOXB1 Transcription Factors | 1 | 2016 | 283 | 0.030 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2021 | 1149 | 0.030 |
Why?
|
| Lung Compliance | 1 | 1995 | 207 | 0.030 |
Why?
|
| Hospitals, County | 1 | 2014 | 18 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 784 | 0.030 |
Why?
|
| Insufflation | 1 | 1995 | 64 | 0.030 |
Why?
|
| Luminescent Proteins | 1 | 2017 | 839 | 0.030 |
Why?
|
| Particle Size | 1 | 2019 | 1633 | 0.030 |
Why?
|
| Benzylamines | 1 | 2015 | 251 | 0.030 |
Why?
|
| Models, Statistical | 3 | 2019 | 5098 | 0.030 |
Why?
|
| Disaster Planning | 1 | 2020 | 557 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2012 | 1442 | 0.030 |
Why?
|
| Actins | 1 | 2022 | 2059 | 0.030 |
Why?
|
| Zalcitabine | 1 | 1994 | 43 | 0.030 |
Why?
|
| Program Development | 1 | 2020 | 1298 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 3530 | 0.030 |
Why?
|
| Benzoates | 1 | 2015 | 213 | 0.030 |
Why?
|
| Factor IXa | 1 | 1993 | 19 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2015 | 8717 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 856 | 0.030 |
Why?
|
| T-Box Domain Proteins | 1 | 2016 | 471 | 0.030 |
Why?
|
| Didanosine | 1 | 1994 | 151 | 0.030 |
Why?
|
| Peptide Library | 1 | 2015 | 351 | 0.030 |
Why?
|
| New Zealand | 1 | 2014 | 360 | 0.030 |
Why?
|
| Nitro Compounds | 1 | 2013 | 74 | 0.030 |
Why?
|
| Evolution, Molecular | 3 | 2007 | 1893 | 0.030 |
Why?
|
| Spine | 1 | 2021 | 1139 | 0.030 |
Why?
|
| Sodium | 1 | 2019 | 1594 | 0.030 |
Why?
|
| CHO Cells | 2 | 2007 | 1376 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2006 | 4522 | 0.030 |
Why?
|
| Thrombophilia | 1 | 2016 | 308 | 0.030 |
Why?
|
| Nephrotic Syndrome | 1 | 1997 | 381 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2010 | 9410 | 0.030 |
Why?
|
| Age Distribution | 2 | 2009 | 2870 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 1994 | 455 | 0.030 |
Why?
|
| Microsurgery | 1 | 1999 | 798 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 857 | 0.030 |
Why?
|
| Dinucleoside Phosphates | 1 | 2013 | 71 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2016 | 853 | 0.030 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 1995 | 236 | 0.030 |
Why?
|
| Superinfection | 1 | 1993 | 61 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2019 | 1531 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2020 | 822 | 0.030 |
Why?
|
| Heart Failure | 1 | 2017 | 11877 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 1999 | 836 | 0.030 |
Why?
|
| Cricetinae | 2 | 2007 | 2415 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2017 | 492 | 0.030 |
Why?
|
| Informed Consent | 1 | 2019 | 1010 | 0.030 |
Why?
|
| Seizures | 1 | 2005 | 2996 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 733 | 0.030 |
Why?
|
| Glycosylation | 1 | 2015 | 1099 | 0.030 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2017 | 426 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2013 | 416 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2015 | 751 | 0.030 |
Why?
|
| Leptin | 1 | 2020 | 1599 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2013 | 456 | 0.020 |
Why?
|
| Postpartum Period | 1 | 2019 | 1198 | 0.020 |
Why?
|
| Retreatment | 1 | 2014 | 598 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2013 | 432 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 1063 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2021 | 4280 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2020 | 2505 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 2513 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2016 | 771 | 0.020 |
Why?
|
| Boston | 2 | 2018 | 9360 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2017 | 1673 | 0.020 |
Why?
|
| Rats, Wistar | 1 | 2016 | 1885 | 0.020 |
Why?
|
| Cell Survival | 2 | 2014 | 5750 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 474 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 2015 | 505 | 0.020 |
Why?
|
| Veterans | 2 | 2016 | 2666 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 478 | 0.020 |
Why?
|
| Catalysis | 1 | 2013 | 766 | 0.020 |
Why?
|
| Forecasting | 1 | 2020 | 2936 | 0.020 |
Why?
|
| Random Allocation | 1 | 2016 | 2394 | 0.020 |
Why?
|
| Brefeldin A | 1 | 2011 | 68 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2017 | 956 | 0.020 |
Why?
|
| Flow Cytometry | 2 | 2013 | 5891 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 1244 | 0.020 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 640 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2020 | 2629 | 0.020 |
Why?
|
| Primates | 1 | 2013 | 519 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 1994 | 911 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1991 | 775 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1991 | 848 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2021 | 2116 | 0.020 |
Why?
|
| Pedigree | 1 | 2018 | 4539 | 0.020 |
Why?
|
| Physician's Role | 1 | 2017 | 923 | 0.020 |
Why?
|
| Urban Population | 1 | 2018 | 2044 | 0.020 |
Why?
|
| Infant | 3 | 2018 | 36485 | 0.020 |
Why?
|
| Heteroduplex Analysis | 1 | 2010 | 9 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 382 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2018 | 26396 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 766 | 0.020 |
Why?
|
| Atrophy | 1 | 2015 | 1631 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 5794 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2017 | 1248 | 0.020 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1993 | 520 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 3511 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1991 | 705 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 447 | 0.020 |
Why?
|
| Educational Status | 1 | 2017 | 2511 | 0.020 |
Why?
|
| Receptors, KIR2DL2 | 1 | 2009 | 6 | 0.020 |
Why?
|
| Receptors, KIR2DL3 | 1 | 2009 | 15 | 0.020 |
Why?
|
| Fear | 1 | 2018 | 1496 | 0.020 |
Why?
|
| Cell Movement | 1 | 2022 | 5203 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 11217 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2019 | 1399 | 0.020 |
Why?
|
| Phenylthiourea | 1 | 2008 | 10 | 0.020 |
Why?
|
| Lung Transplantation | 1 | 1999 | 1310 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 1197 | 0.020 |
Why?
|
| Insulin | 1 | 2003 | 6602 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 1321 | 0.020 |
Why?
|
| Molecular Biology | 1 | 1993 | 573 | 0.020 |
Why?
|
| Abdomen | 1 | 1995 | 1138 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2011 | 389 | 0.020 |
Why?
|
| Amino Acids | 2 | 2007 | 1712 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2019 | 4186 | 0.020 |
Why?
|
| Introns | 1 | 1991 | 965 | 0.020 |
Why?
|
| Histones | 1 | 2019 | 2597 | 0.020 |
Why?
|
| Glucose | 1 | 2020 | 4341 | 0.020 |
Why?
|
| Reference Values | 1 | 2016 | 4918 | 0.020 |
Why?
|
| Coma | 1 | 2012 | 485 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 1995 | 947 | 0.020 |
Why?
|
| Protein Interaction Mapping | 1 | 2012 | 621 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2014 | 2063 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2021 | 4045 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 2011 | 350 | 0.020 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 1993 | 1117 | 0.020 |
Why?
|
| Phosphates | 1 | 2011 | 765 | 0.020 |
Why?
|
| Risk | 1 | 2020 | 9606 | 0.020 |
Why?
|
| Indoles | 1 | 2016 | 1836 | 0.020 |
Why?
|
| Bone Density | 1 | 2021 | 3573 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type I | 1 | 2008 | 97 | 0.020 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2008 | 72 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2008 | 163 | 0.020 |
Why?
|
| Activin Receptors, Type I | 1 | 2008 | 133 | 0.020 |
Why?
|
| Activin Receptors, Type II | 1 | 2008 | 122 | 0.020 |
Why?
|
| Gestational Age | 1 | 2016 | 3618 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2014 | 5796 | 0.020 |
Why?
|
| Education | 1 | 2010 | 531 | 0.020 |
Why?
|
| Genes, MHC Class I | 1 | 2007 | 236 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 2628 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 1995 | 1085 | 0.020 |
Why?
|
| Pain | 1 | 2002 | 5101 | 0.020 |
Why?
|
| Tretinoin | 1 | 2010 | 524 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2007 | 363 | 0.020 |
Why?
|
| Serotyping | 1 | 2007 | 331 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 1641 | 0.020 |
Why?
|
| Interferon-beta | 1 | 2008 | 348 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1991 | 1741 | 0.020 |
Why?
|
| Prisoners | 1 | 2009 | 315 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2007 | 1057 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 1677 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2007 | 255 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5332 | 0.020 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2005 | 89 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 3232 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 3700 | 0.020 |
Why?
|
| Thrombosis | 1 | 1999 | 2954 | 0.020 |
Why?
|
| Dimerization | 1 | 2007 | 882 | 0.020 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2008 | 481 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 3964 | 0.020 |
Why?
|
| Cricetulus | 1 | 2007 | 810 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 1894 | 0.010 |
Why?
|
| Long-Term Care | 1 | 2009 | 631 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2005 | 612 | 0.010 |
Why?
|
| Research Design | 1 | 2020 | 6210 | 0.010 |
Why?
|
| Communication | 1 | 2019 | 3904 | 0.010 |
Why?
|
| Echocardiography | 1 | 2017 | 5042 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 793 | 0.010 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2007 | 335 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2007 | 896 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 829 | 0.010 |
Why?
|
| Health Status | 1 | 2017 | 4091 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2009 | 1864 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2009 | 1947 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2017 | 3934 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 4424 | 0.010 |
Why?
|
| Shigella sonnei | 1 | 1984 | 7 | 0.010 |
Why?
|
| Cysteine | 1 | 2009 | 896 | 0.010 |
Why?
|
| Plasmapheresis | 1 | 2005 | 205 | 0.010 |
Why?
|
| Candida | 1 | 2005 | 171 | 0.010 |
Why?
|
| Dermatology | 1 | 2014 | 905 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2009 | 2276 | 0.010 |
Why?
|
| Decision Making | 1 | 2018 | 3951 | 0.010 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 1 | 1984 | 40 | 0.010 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2007 | 381 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2020 | 8940 | 0.010 |
Why?
|
| Herpesvirus 2, Human | 1 | 2005 | 191 | 0.010 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1983 | 40 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 1729 | 0.010 |
Why?
|
| Critical Care | 1 | 2016 | 2714 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 498 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2006 | 602 | 0.010 |
Why?
|
| Sclerosing Solutions | 1 | 1983 | 79 | 0.010 |
Why?
|
| Serum Albumin | 1 | 2006 | 676 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 717 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5363 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2011 | 872 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2005 | 1647 | 0.010 |
Why?
|
| Sepsis | 1 | 2016 | 2605 | 0.010 |
Why?
|
| Salmonella typhi | 1 | 1984 | 200 | 0.010 |
Why?
|
| Ligation | 1 | 1983 | 446 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2002 | 207 | 0.010 |
Why?
|
| Therapeutic Irrigation | 1 | 1983 | 297 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 1984 | 400 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2017 | 8531 | 0.010 |
Why?
|
| Vasopressins | 1 | 1983 | 358 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2015 | 3968 | 0.010 |
Why?
|
| Cadaver | 1 | 2005 | 1362 | 0.010 |
Why?
|
| Ileum | 1 | 2003 | 558 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2005 | 751 | 0.010 |
Why?
|
| Injections | 1 | 2003 | 839 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 2008 | 10254 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2001 | 386 | 0.010 |
Why?
|
| Duodenum | 1 | 2003 | 495 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 8535 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 2 | 1998 | 1969 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 1991 | 3599 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 7469 | 0.010 |
Why?
|
| Herpesvirus 1, Human | 1 | 2005 | 743 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 2005 | 1079 | 0.010 |
Why?
|
| Methotrexate | 1 | 2005 | 1718 | 0.010 |
Why?
|
| Military Personnel | 2 | 2000 | 1261 | 0.010 |
Why?
|
| Transplantation, Heterotopic | 1 | 1999 | 175 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 2209 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 1991 | 4401 | 0.010 |
Why?
|
| Diet | 1 | 2016 | 8089 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2016 | 4881 | 0.010 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 104 | 0.010 |
Why?
|
| Antigens, Bacterial | 1 | 1984 | 1148 | 0.010 |
Why?
|
| Cerebellum | 1 | 2005 | 1521 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1993 | 4854 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2000 | 683 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 2002 | 596 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1983 | 1666 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1983 | 1308 | 0.010 |
Why?
|
| Enalapril | 1 | 1997 | 317 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 3591 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2006 | 6844 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2005 | 2926 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 1999 | 992 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2001 | 1319 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2003 | 2568 | 0.010 |
Why?
|
| Peritonitis | 1 | 1996 | 368 | 0.010 |
Why?
|
| AIDS-Related Complex | 1 | 1994 | 107 | 0.010 |
Why?
|
| Virulence | 1 | 1997 | 1294 | 0.010 |
Why?
|
| Rheumatoid Factor | 1 | 1992 | 185 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2003 | 3043 | 0.010 |
Why?
|
| Pressure | 1 | 1995 | 1172 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1994 | 831 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1999 | 2391 | 0.010 |
Why?
|
| Smoking | 1 | 2006 | 9081 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1994 | 963 | 0.000 |
Why?
|
| Reoperation | 1 | 1997 | 4325 | 0.000 |
Why?
|
| Neurons | 1 | 2005 | 9517 | 0.000 |
Why?
|
| Conjugation, Genetic | 1 | 1984 | 116 | 0.000 |
Why?
|
| Dysentery, Bacillary | 1 | 1984 | 73 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1984 | 1309 | 0.000 |
Why?
|
| Typhoid Fever | 1 | 1984 | 195 | 0.000 |
Why?
|
| Lipopolysaccharides | 1 | 1984 | 2217 | 0.000 |
Why?
|